3-Fluoro-4-methyl-2-pyridylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-Fluoro-4-methyl-2-pyridylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide
• 英文别名: 2-[6-Chloro-3-(2,2-difluoro-2-pyridin-2-yl-ethylamino)-2-oxo-2H-pyrazin-1-yl]-N-(3-fluoro-4-methyl-pyridin-2-ylmethyl)-acetamide；2-[6-chloro-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-oxopyrazin-1-yl]-N-[(3-fluoro-4-methylpyridin-2-yl)methyl]acetamide
• 化学式: C₂₀H₁₈ClF₃N₆O₂
• 分子量: 466.85
• InChiKey: ZRFQFOOQGLYZEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  99.6
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-吡啶乙酸乙酯 在 10percent Pd/C 氢氧化钾 、 sodium tetrahydroborate 、 N-氯代丁二酰亚胺 、 sodium azide 、 N-羟基-7-氮杂苯并三氮唑 、 2,6-二叔丁基-4-甲基吡啶 、 氢气 、 双(三甲基硅烷基)氨基钾 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 乙酸乙酯 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 10.75h， 生成 3-Fluoro-4-methyl-2-pyridylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide
  参考文献：
  名称：

  Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines

  摘要：

  Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which resulted in the,modification of each of the three principal components (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified which exhibit high levels of oral bioavailability and long plasma half-lives.

  DOI：

  10.1021/jm020311f

文献信息

• PYRAZINONE THROMBIN INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1189899B1

  公开（公告）日：2003-02-12
• US6455532B1
  申请人：——

  公开号：US6455532B1

  公开（公告）日：2002-09-24
• [EN] PYRAZINONE THROMBIN INHIBITORS<br/>[FR] INHIBITEURS DE THROMBINE A BASE DE PYRAZINONE
  申请人：MERCK & CO INC

  公开号：WO2000075134A1

  公开（公告）日：2000-12-14

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having structure (I): where A is (II), (III), or (IV) wherein Y?1 and Y2¿ are independently hydrogen, C¿1-4? alkyl, C1-4 alkoxy, FuHvC(CH2)0-1 O-, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1; C3-7 cycloalkyl, thio C1-4 alkyl, C1-4 sulfinylalkyl, C1-4 sulfonylalkyl, halogen, cyano, or trifluoromethyl, and wherein b is 0 or 1.
• Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines
  作者：Christopher S. Burgey、Kyle A. Robinson、Terry A. Lyle、Philip E. J. Sanderson、S. Dale Lewis、Bobby J. Lucas、Julie A. Krueger、Rominder Singh、Cynthia Miller-Stein、Rebecca B. White、Bradley Wong、Elizabeth A. Lyle、Peter D. Williams、Craig A. Coburn、Bruce D. Dorsey、James C. Barrow、Maria T. Stranieri、Marie A. Holahan、Gary R. Sitko、Jacquelynn J. Cook、Daniel R. McMasters、Colleen M. McDonough、William M. Sanders、Audrey A. Wallace、Franklin C. Clayton、Dennis Bohn、Yvonne M. Leonard、Theodore J. Detwiler,、Joseph J. Lynch,、Youwei Yan、Zhongguo Chen、Lawrence Kuo、Stephen J. Gardell、Jules A. Shafer、Joseph P. Vacca

  DOI：10.1021/jm020311f

  日期：2003.2.1

  Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phenethylamino)-6-methylpyrazinone acetamide template (e.g., 1) which resulted in the,modification of each of the three principal components (i.e., P1, P2, P3) comprising this series. As a result of these studies, several potent thrombin inhibitors (e.g., 20, 24, 25) were identified which exhibit high levels of oral bioavailability and long plasma half-lives.